Haemoglobin A1c
This product is used on NEPHSTAR® protein analysis system for quantitative determination of human Haemoglobin A1c (HbA1c) percentage to total Haemoglobin in whole blood
Diabetes Mellitus is a chronic disease characterized by a hyperglycemia. The consequences are metabolism disorders of carbohydrates, lipids and proteins. The risk of complications associated with diabetes, including nephropathy, retinopathy and cardiovascular diseases, increases in patients with poor metabolic control. In the diabetic patients, where blood glucose levels are elevated, HbA1c is formed as a consequence of the non-enzymatic glycation of the N-terminus of the β -chain of haemoglobin molecule. The level of HbA1c is proportional to the level of glucose in the blood and has been widely accepted as an indicator of the mean daily blood glucose concentration over the preceding 6-8 weeks. It is therefore, a long-term indicator of diabetic control, whereas, the measurement of blood glucose is only a short-term.
The HbA1c kit is a quantitative nephelometric test directly for the percentage of glycated hemoglobin (HbA1c) to total haemoglobin (HbT). Total haemoglobin and HbA1c have the same unspecific absorption rate to latex particles. When mouse anti-human HbA1c monoclonal antibody is added, latex-HbA1c-mouse anti-human HbA1c antibody complex is formed. Agglutination is formed when goat anti-mouse igG polyconal antibody interacts with the monoclonal antibody. The amount of agglutination is measured by nephelometry. The HbA1c percentage value is obtained from a calibration curve.
Cohen P.M. Perspective: measurement of Circulating Glycated Protein to Monitor Intermediate – Term Changes in Glycaemic Control Eur J Clin Chem. Clin. Biochem. 1992:30 (12): 851 – 859